Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Reddy’s Earnings Plunge On German Unit Charge, Increased Generic Competition

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Dr Reddy's Laboratories, India's second-biggest drugmaker, said third quarter earnings and revenues plunged on lower-than-expected earnings in Germany and increased competition as it changes its mix of generic drug products
Advertisement

Related Content

Dr. Reddy’s Sees Profit Drop As Pricing Pressure Hits Generics Industry
Dr. Reddy’s Sees Profit Drop As Pricing Pressure Hits Generics Industry
Dr Reddy’s Sees Revenue Growth Of 25 Percent This Financial Year, Improved Profitability
Dr Reddy’s Sees Revenue Growth Of 25 Percent This Financial Year, Improved Profitability
India's Dr. Reddy's Laboratories Buys U.K. Dow Chemical Drug Units To Bolster Contract Research
India's Dr. Reddy's Laboratories Buys U.K. Dow Chemical Drug Units To Bolster Contract Research
Indian Drug Majors Settle Generic Lawsuits
Indian Drug Majors Settle Generic Lawsuits
Teva To Expand Presence In India
Dr. Reddy's Launches Rituxan Generic
Advertisement
UsernamePublicRestriction

Register

SC066710

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel